Table 2.
Utilization of Invasive Angiography, Revascularization Strategies, and Antiplatelet Therapies at Discharge
| Y2020 (n = 227) | Y2021 (n = 359) | P Valuea | |
|---|---|---|---|
| No angiogram | 52 (23.0) | 49 (14.0) | 0.004 |
| Patients undergoing invasive angiography, n = 485 | |||
| Reperfusion strategy | 175 | 310 | 0.7 |
| CABG | 3 (1.7) | 5 (1.6) | |
| Facilitated/rescue PCI | 7 (4.0) | 11 (3.5) | |
| Medical therapy | 34 (19.0) | 78 (25.0) | |
| Primary PCI | 125 (71.0) | 206 (66.0) | |
| Thrombolytics | 6 (3.4) | 10 (3.2) | |
| Multivessel CAD | 69 (49.0) | 111 (49.0) | 0.9 |
| Primary PCI (survived to hospital discharge and complete antiplatelet data) | 89 (73.0) | 144 (73.0) | 0.45 |
| Clopidogrel | 31 (34.0) | 39 (27.0) | |
| Prasugrel | 10 (11.0) | 12 (8.0) | |
| Ticagrelor | 48 (53.0) | 93 (64.0) |
Values are n (%) or n.
CABG = coronary artery bypass graft surgery; other abbreviations as in Table 1.
a
Not adjusted for multiple comparisons.